DIA-CAL-100

antibody from ONCOdianova

Targeting: CALR cC1qR, CRT, FLJ26680, RO, SSA

Western blot (Recommended by provider)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

DIA-CAL-100

Provider

ONCOdianova

Product name

Anti-mutant CALR (Human), clone CAL2

Antibody type

Monoclonal

Description

Mouse monoclonal antibody (IgG2a), clone CAL2 (CAL2®), directed against the C-neoterminus of mutated calreticulin (CALR), for immunohistochemistry on formalin-fixed, paraffin-embedded (FFPE) tissue, including bone marrow with or without EDTA decalcification, and for Western blot. Lyophilisate, purified from culture supernatant. Also available as DIA-CAL-250 (250 µl). Immunogen: C-neoterminus of mutated CALR. RRID: AB_2800528.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

CAL2

Vial size

100 µl

Storage

Reconstituted at 2–8 °C (several weeks stable); long term at −20 / −80 °C (at least one year at −20 °C); avoid repeated freeze/thaw cycles.

Handling

Buffer: PBS, pH 7.4, 2% BSA, 0.05% sodium azide.

References

Submitted references

Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.

Kalmer M, Wirths C, Lemanzyk R, Piergentili A, Mönnig M, Zhou C, Junge B, Goßen J, Gupta S, Schulz L, Spitzer A, Tillmann S, Kricheldorf K, Schifflers J, Pannen K, Galauner A, Piehler J, Pecquet C, de Toledo MAS, Constantinescu SN, Rossetti G, Koschmieder S, Chatain N
Leukemia 2026 Sep 24;

---

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.

Pesini C, Gil-Bellido M, S Millan L, Oñate C, Calvo-Pérez A, Santiago L, Iglesias E, Bernal JP, Araujo-Voces M, Paz Artigas L, García-Martínez L, Roig FJ, Movilla Meno N, Garcia-Aznar JM, Menéndez-Jandula B, Olave MT, Azaceta Reinares G, Garrote M, Alvarez-Larrán A, Gálvez EM, Sánchez Martínez D, Arias MA, Pardo J, Ramirez-Labrada A
Journal for immunotherapy of cancer 2026 Jan 13;14(1)

---

Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 CALR-Mutated MPN.

Wang YH, Chen YJ, Lai YH, Wang MC, Chen YY, Wu YY, Yang YR, Tsou HY, Li CP, Hsu CC, Huang CE, Chen CC
International journal of molecular sciences 2023 May 14;24(10)

---

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.

Foßelteder J, Pabst G, Sconocchia T, Schlacher A, Auinger L, Kashofer K, Beham-Schmid C, Trajanoski S, Waskow C, Schöll W, Sill H, Zebisch A, Wölfler A, Thomas D, Reinisch A
Leukemia 2023 Apr;37(4):843-853

---

Calreticulin Immunohistochemistry in Myeloproliferative Neoplasms - Evolution of a New Cost-Effective Diagnostic Tool: A Retrospective Study with Histological and Molecular Correlation.

Roy S, Manipadam MT, Balasubramanian P
Turk patoloji dergisi 2022;38(1):25-33

---

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.

Tvorogov D, Thompson-Peach CAL, Foßelteder J, Dottore M, Stomski F, Onnesha SA, Lim K, Moretti PAB, Pitson SM, Ross DM, Reinisch A, Thomas D, Lopez AF
EMBO reports 2022 Apr 5;23(4):e52904

---

Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.

Ali H, Puccio I, Akarca AU, Bob R, Pomplun S, Keong Wong W, Gupta R, Sekhar M, Lambert J, Al-Masri H, Stein H, Marafioti T
International journal of experimental pathology 2021 Feb;102(1):45-50

---

Calreticulin Mutation by Immunohistochemistry: Can It Replace PCR?

Gupta A, Sazawal S, Mahapatra M, Pati HP, Saxena R
Applied immunohistochemistry & molecular morphology : AIMM 2020 Sep;28(8):621-626

---

Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.

Rahman K, Chandra D, Singh MK, Gupta R, Sharma A, Paul P, Kumar S, Sharma S, Nityanand S
International journal of laboratory hematology 2020 Oct;42(5):604-611

---

CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients.

Bonifacio M, Montemezzi R, Parisi A, De Matteis G, Bertorelle R, Scaffidi L, Candiotto C, Lippi G, Zamò A, Chilosi M, Pizzolo G, Scarpa A, Krampera M
Annals of hematology 2019 Oct;98(10):2339-2346

---

The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation.

Mansier O, Prouzet-Mauléon V, Jégou G, Barroso K, Raymundo DP, Chauveau A, Dumas PY, Lagarde V, Turcq B, Pasquet JM, Viallard JF, James C, Praloran V, Voutetakis K, Chatziioannou A, Mahon FX, Chevet E, Lippert E
Cancers 2019 Dec 2;11(12)

---

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.

Mózes R, Gángó A, Sulák A, Vida L, Reiniger L, Timár B, Krenács T, Alizadeh H, Masszi T, Gaál-Weisinger J, Demeter J, Csomor J, Matolcsy A, Kajtár B, Bödör C
Pathology 2019 Apr;51(3):301-307

---

CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.

Nomani L, Bodo J, Zhao X, Durkin L, Loghavi S, Hsi ED
American journal of clinical pathology 2016 Oct;146(4):431-8

---

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.

Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N
Journal of hematology & oncology 2016 May 13;9(1):45

---

Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.

Andrici J, Farzin M, Clarkson A, Sioson L, Sheen A, Watson N, Toon CW, Koleth M, Stevenson W, Gill AJ
Pathology 2016 Jun;48(4):319-24

---

A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies.

Stein H, Bob R, Dürkop H, Erck C, Kämpfe D, Kvasnicka HM, Martens H, Roth A, Streubel A
Leukemia 2016 Jan;30(1):131-5